ADA 2021: Key Studies Influencing Diabetes Care
  • CME

June 25-29, 2021; Virtual
Read these expert commentaries from Anne Peters, MD, and Martin J. Abrahamson, MD, FACP, summarizing key data from ADA 2021 and how it may influence your practice.
Martin J. Abrahamson, MD, FACP
Anne Peters, MD
Physicians: maximum of 0.5 AMA PRA Category 1 Credits
Released: August 6, 2021 Expiration: August 5, 2022

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Apply recently presented data to clinical practice to expand treatment options and improve outcomes for patients with type 1 and type 2 diabetes
  • Discuss new data on novel agents and therapeutic approaches for patients with type 1 or type 2 diabetes

Acknowledgements

Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by an educational grant from
Merck

Information on this Educational Activity

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Faculty

Anne Peters, MD

Director, USC Clinical Diabetes Program
Professor of Clinical Medicine
Keck School of Medicine of USC
Los Angeles, California

Anne Peters, MD, has disclosed that she has received consulting fees from Abbott Diabetes Care, Biorad, Lilly, MannKind, Merck, Novo Nordisk, and Zealand; has received funds for research support from Abbott Diabetes Care and Dexcom; and has ownership interest in Omada Health and Teladoc.
Martin J. Abrahamson, MD, FACP

Associate Professor of Medicine
Harvard Medical School
Director, Division of CME
Beth Israel Deaconess Medical Center
Boston, Massachusetts

Martin J. Abrahamson, MD, FACP, has disclosed that he has received consulting fees from Novo Nordisk and WebMD Health Services.

Staff

Robin Black, PharmD, BCACP

Scientific Director

Robin Black, PharmD, BCACP has no relevant conflicts of interest to report.
Kiran D. Mir-Hudgeons, PhD

Manager, Editorial Operations

Kiran D. Mir-Hudgeons, PhD, has no relevant conflicts of interest to report.
Ruth Cohen Cooper, CHCP

Vice President, Science and Strategy

Ruth Cohen Cooper, CHCP, has no relevant conflicts of interest to report.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Target Audience

This program is intended for physicians and other healthcare providers who care for patients with type 1 and type 2 diabetes.

Goal

The goal of this activity is to improve learners’ understanding of how to optimally apply recent practice-changing findings in the treatment of patients with diabetes.

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

CCO designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Program Medium

This program has been made available online.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 0.5 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from August 06, 2021, through August 05, 2022:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Related Content

From Dr. Carol Hatch Wysham and Clinical Care Options (CCO), expert commentary on emerging data on tirzepatide for type 2 diabetes

Carol Hatch Wysham, MD Released: September 21, 2021

This is the snippet that appears below the blue link in Google search. Words that matched the user query get pulled out in bold. From Clinical Care Options (CCO) and Dr. Ananda Basu, a brief commentary on barriers to use of diabetes technology

Ananda Basu, MD, FRCP Released: September 15, 2021

Downloadable slides from Clinical Care Options (CCO) featuring expert insights on the clinical trial data supporting the use of tirzepatide in T2D

Carol Hatch Wysham, MD Released: September 2, 2021

Short video from Clinical Care Options (CCO) featuring expert insights on the clinical trial data supporting the use of tirzepatide in T2D

Carol Hatch Wysham, MD Physicians: maximum of 0.25 AMA PRA Category 1 Credits Registered Nurses: 0.25 Nursing contact hours Pharmacists: 0.25 contact hours (0.025 CEUs) Registered Dieticians/Dietetic Technicians, Registered: maximum of 0.25 CPEU(s) Released: September 2, 2021 Expired: September 1, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue